Overview

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is an evaluation of the effectiveness of darbepoetin alpha in treating anemia of MDS patients with an International Prognostic Scoring System (IPSS) score of low or intermediate 1.
Phase:
Phase 2
Details
Lead Sponsor:
Groupe Francophone des Myelodysplasies
Treatments:
Darbepoetin alfa